Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.

Alessandra Boccaccino,Daniele Rossini,Alessandra Raimondi,Martina Carullo,Sara Lonardi,Federica Morano,Daniele Santini,Gianluca Tomasello,Monica Niger,Alberto Zaniboni,Francesca Daniel,Sara Bustreo,Letizia Procaccio,Matteo Clavarezza,Samanta Cupini, Michela Libertini,Federica Palermo,Filippo Pietrantonio,Chiara Cremolini

European journal of cancer (Oxford, England : 1990)（2023）

引用 0|浏览27

暂无评分

摘要

Most of chemotherapy-related AEs (except for HFS and neuropathy) reach the highest level in the first cycles, then decrease, probably due to their active clinical management. Transition to maintenance allows relief from most AEs, especially with bevacizumab-based regimens, while anti-EGFR-related AEs may persist.

查看译文

关键词

mcrc,toxicity,adverse events,treatments,toxt,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要